clinical trial · NCT04009499
A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
UCB Biopharma SRL·phase3·completed·n = 1,131
Psoriatic ArthritisBimekizumab
brief summary
This is a study to assess the long-term safety, long-term efficacy and tolerability of bimekizumab administered subcutaneously (sc) in adult subjects with psoriatic arthritis (PsA).
started
Aug 13, 2019
primary completion
May 26, 2026
completion
May 26, 2026
last updated
Jun 1, 2026
official title
A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol